Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STNM01 intratumoral administration by EUS-FNI in unresectable pancreatic cancer
jRCT2031190055Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2019
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of stnm01 in pancreatic cancer (PC), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Dose-limiting toxicity (DLT) at week 6. Started Apr 2019; status: active, not recruiting.
02
Drugs
stnm01
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031190055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190055.